scholarly journals Cost-Effectiveness of Afatinib, Gefitinib, Erlotinib, and Pemetrexed-Based Chemotherapy as First-Line Treatments for Egfr Mutation Positive, Advanced Non-Small Cell Lung Cancer in China

2017 ◽  
Vol 20 (9) ◽  
pp. A440-A441
Author(s):  
J Zhu ◽  
M Ye ◽  
J Fu ◽  
B Wu ◽  
Y Chu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line

scholarly journals First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer

2019 ◽  
Vol 18 ◽  
pp. 100113 ◽  
Author(s):  
Kazuma Kishi ◽  
Hiroshi Sakai ◽  
Takashi Seto ◽  
Toshiyuki Kozuki ◽  
Makoto Nishio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document